Evaluation of the Suitability of Kinetic Chromogenic LAL Assay for Determination of Endotoxin Levels in Heparin Sodium Injection
Trends in Peptide and Protein Sciences,
Vol. 1 No. 2 (2016),
17 January 2017
,
Page 73-82
https://doi.org/10.22037/tpps.v1i2.15308
Abstract
Determination of the levels of endotoxins in injectable products has always been one of the concerns of regulatory authorities and manufacturers. Since a number of pharmaceuticals interfere with the LAL test to some degree, overcoming the inhibition or enhancement properties of a product is required as part of the validation of the LAL test for use in the final release testing of parenteral products. In this study, interference profile of Heparin injection in quantitative chromogenic LAL test was evaluated and the method of overcoming was investigated and validated. The results indicate that dilution as the most widely used technique for overcoming interference could not eliminate LAL interference in the aforementioned medicinal product. The inhibitory nature of heparin occurs due to its anticoagulant properties and can be overcome by using divalent cations such as magnesium. Three concentrations of magnesium chloride were evaluated for elimination of heparin’s inhibitory effect. All three concentrations studied (5, 10 and 25 mM) could effectively eliminate the inhibitory effects of heparin. Hence, one-way analysis of variance was used to determine statistically significant differences between these three concentrations. The results of ANOVA statistical method showed the optimal recovery of spiked endotoxin was at a concentration of 10 mM of magnesium chloride. In consequence, chromogenic LAL test using 10 mM of magnesium chloride as diluent could be a validated method of choice for heparin LAL assay.
Highlights
- Bacterial endotoxins are important contaminants associated with injectable pharmaceuticals.
- Kinetic chromogenic LAL assay was used as the method to determine endotoxin levels in heparin injections.
- Selectivity, linearity and repeatability of the endotoxin chromogenic method was validated.
- Endotoxin
- Heparin injection
- Inhibitory effect
- Kinetic chromogenic LAL assay
- Validation
How to Cite
References
Chałupniak, A., Waszczuk, K., Hałubek-Głuchowska, K., Piasecki, T., Gotszalk, T. and J. Rybka, (2014). ″Application of quartz tuning forks for detection of endotoxins and Gram-negative bacterial cells by monitoring of Limulus Amebocyte Lysate coagulation.″ Biosensors and Bioelectronics, 58: 132-137.
Cooper, J. (1990). ″Resolving LAL Test interferences.″ Journal of Parentral Science and Technology, 44(1): 5-13.
Cooper, J., Weary, M. and F. Jordan, (1997). ″The impact of non-endotoxin LAL-reactive materials on Limulus amebocyte lysate analyses.″ PDA Journal of Pharmaceutical Science and Technology, 51(1): 2-6.
Dawson, M. (1995). ″Maximum valid dilution and minimum valid concentration.″ LAL Update, 13(3): 1-6.
Dawson, M. (2005). ″Interference with the LAL test and how to address it.″LAL Update, 22(3): 1-6.
British Pharmacopoeia Commission, 2012. ″Formulated Preparation: Specific Monograph, Heparin Injection.″ In: British Pharmacopoeia Commission. British Pharmacopoeia 2012: volume III. London TSO.
British Pharmacopoeia Commission, 2012. ″Apendix XIV: C. Test for Bacterial Endotoxins (LAL Test).″ In: British Pharmacopoeia Commission. British Pharmacopoeia 2012: volume V. appendices. London TSO.
Fernando, F., Sheila, R. A. and M. Shirleyde, (2013). ″Intralaboratory validation of kinetic chromogenic Limulus amebocytelysate assay for bacterial endotoxin determination in anti-bothropic serum.″ Journal of Pharmaceutical and Biomedical Analysis, 85: 93-98.
Food and Drug Administration (1992). ″Guidline on validation of the limulus Amebocyte Lysate test as end-product endotoxin test for human and animal parentral drugs, biological products and medical devices″, Center for Drug Evaluation and Research, Department of Health and Human Services, Food and Drug Administration, Rockville, MD, USA.
Joiner, T., Kraus, P. F. and T. C. Kupiec, (2002). ″Comparison of endotoxin testing methods for pharmaceutical products.″ International Journal of Pharmaceutical Componding, 6(6): 408-409.
Lonza company (2012a). ″Kinetic-QCL™ LAL Assay Make Critical Decisions with Confidence: Quantitative Endotoxin Results.″, U.S: Pharma & Biotech. Available at: http://www.lonza.com.
Lonza company (2012b). ″Manuals Limulus Amebocyte lysate (LAL) Kinetic-QCL.″, U.S: Pharma & Biotech. Available at: http:// www.lonza.com.
Lonza company (2012c). ″Overcoming assay inhibition or enhancement.″, Scientific support, U.S: Pharma & Biotech. Available at: http://www.lonza.com.
Rustichelli, D., Castiglia, S., Gunetti, M., Mareschi, K., Signorino, E., Muraro, M., Castello, L., Sanavio, F., Leone, M., Ferrero, I. and F. Fagioli, (2013). ″Validation of analytical methods in compliance with good manufacturing practice: a practical approach.″ Journal of Translational Medicine, 11: 197.
United States Pharmacopeia and National Formulary (USP 35-NF 30). General Chapter <85>, Bacterial Endotoxin Test. Rockville, MD: United States Pharmacopeia Convention, 2014, pp. 5625-5629.
Williams, K. L. (2007). ″Limulus Amebocyte Lysate Assay Development, Validation, and Regulation.” In: Endotoxins, Pyrogens, LAL Testing and Depyrogenation. 3rd Ed. Indianapolis: Eli Lilly & Company. pp. 221-260.
Yuu, F., Tetsuhiro, T. and K. Hirofumi, (2011). ″Saline and buffers minimize the action of interfering factors in the bacterial endotoxin test.″ Analytical Biochemistry, 409: 46-53.
- Abstract Viewed: 1504 times
- PDF Downloaded: 682 times